Validating Ion Mobility-Mass Spectrometry as a Novel High Throughput Screening Method for Protein Tyrosine Kinase Inhibitors

摘要

1. We have shown that we can use IM-MS for screening betwen dierent types of PTK inhibitors. 2. There is the potential for a low false positive rate (estimated to be 20%): -PP2 (predicted to be type I) conrmed type I; -Saracatinib (type I in Src) identied as type II by our screen; -Sorafenib (type II in Raf1) identied by our screen as type I. 3. The +11 data is a more powerful screening tool. 4. Future work will be to use the +11 data to screen large libraries for potential type I and type II in-hibitors 5. We also move to screen other protein tyrosine kinases, such as Src.